title: Therapeutic effect and safety of increasing doses of risperidone (R 64766) in psychotic patients.
abstract: Risperidone (R 64766) was administered during 4 weeks in increasing doses to 17 psychotic patients, to evaluate the hematological and cardiovascular safety, the therapeutic effect, side effects, effects upon endocrinological parameters and the pharmacokinetic profile. Following a placebo wash-out period of 1 week, the initial dose was 10 mg daily, increasing with 5 mg per week until the maximal dose of 25 mg daily was reached during the 4th week of treatment. Doses up to 20 mg daily resulted in a significant improvement of the total BPRS score and of the different BPRS factor scores; with higher doses, no further clinical benefit was achieved except for the hostility and anxiety-depression factor, while sedation became more prominent. No increase of extrapyramidal symptoms was noticed. Except for the sedation observed with higher doses, risperidone was well tolerated. No clinically relevant effects on cardiovascular and ECG parameters were noticed, and except for a slight increase of aspartate aminotransferase and alanine aminotransferase in one patient, no laboratory abnormalities were observed. Prolactin showed an expected increase, while the other endocrinological parameters revealed no changes. Risperidone had a linear pharmacokinetic profile.
authors: Psychiatrisch Instituut St. Jozef, Munsterbilzen, Belgium.
authors: F
authors: F
authors: Mesotten
authors: E
authors: E
authors: Suy
authors: M
authors: M
authors: Pietquin
authors: P
authors: P
authors: Burton
authors: S
authors: S
authors: Heylen
authors: Y
authors: Y
authors: Gelders
mesh_terms: D000328:Adult; D000368:Aged; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D004562:Electrocardiography; D005260:Female; D006728:Hormones / Q000097:blood; D006801:Humans; D007555:Isoxazoles / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010080:Oxazoles / Q000627:therapeutic use*; D010880:Piperidines / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011569:Psychiatric Status Rating Scales; D011618:Psychotic Disorders / Q000188:drug therapy*; D018967:Risperidone
chemical_list: D014150:Antipsychotic Agents; D006728:Hormones; D007555:Isoxazoles; D010080:Oxazoles; D010880:Piperidines; D018967:Risperidone